aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

aTyr Pharma

07/08/2026 21:20

aTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -22 cents.  The mean expectation of eight analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -16 cents to -10 cents per share.
Reported revenue was zero​; analysts expected zero. 
aTyr Pharma Inc's reported EPS for the quarter was a loss of 11 cents​.
The company reported a quarterly loss of $10.31 million.
aTyr Pharma Inc shares had fallen by 15.9% this quarter and lost 35.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 19% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for aTyr Pharma Inc is $3.50, about 85.7% above its last closing price of $0.50
This summary was machine generated from LSEG data August 7 at 08:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.12
-0.11
Beat
Mar. 31 2026 
-0.14
-0.11
Beat
Dec. 31 2025 
-0.18
-0.14
Beat
Sep. 30 2025 
-0.18
-0.26
Missed